Skip to main content

Table 3 Toxicity profile after treatment

From: A phase II study of Endostatin in combination with paclitaxel, carboplatin, and radiotherapy in patients with unresectable locally advanced non-small cell lung cancer

Complications

0

I

II

III

IV

III + IV, % (n)

%(n)

% (n)

% (n)

% (n)

% (n)

Hematological toxicities

 Anemia

32 (6)

26 (5)

32 (6)

11 (2)

0

11 (2)

 Leukopenia

21 (4)

32 (6)

26 (5)

16 (3)

5 (1)

21 (4)

 Neutropenia

16 (3)

32 (6)

26 (5)

21 (4)

5 (1)

26 (5)

 Thrombocytopenia

26 (5)

42 (8)

21 (4)

5 (1)

5 (1)

11 (2)

Non-hematological toxicities

 Nausea

37 (7)

37 (7)

16 (3)

11 (2)

0

11 (2)

 Vomiting

47 (9)

32 (6)

11 (2)

11 (2)

0

11 (2)

 Anorexia

53 (10)

26 (5)

11 (2)

5 (1)

5 (1)

11 (2)

 Hemorrhage

90 (17)

5 (1)

5 (1)

0

0

0

 Fatigue

37 (7)

32 (6)

26 (5)

5 (1)

0

5 (1)

 ALT/AST

89 (15)

16 (3)

5 (1)

0

0

0

 Arrhythmia

63 (12)

37 (7)

0

0

0

0

 Esophagitis

26 (5)

37 (7)

16 (4)

11 (2)

5 (1)

16 (3)

 Pneumonitis

21 (4)

26 (5)

26 (5)

26 (5)

0

26 (5)